The pharma industry reported 70 deals worth $8.3 billion as compared to the last 12-month average (July 2021 to June 2022) of 78 deals worth $13.9 billion, a report from GlobalData has notified.
SD Biosensor and SJL Partners to acquire Meridian Bioscience for a consideration of approximately $1.53 billion; Royalty Pharma to acquire royalty interest in Trelegy from Theravance Biopharma for $1.3 billion in cash up front and up to $300 million in additional payments contingent on the achievement of certain sales milestones; and AstraZeneca to acquire TeneoTwo, including its clinical-stage T-cell engager for a consideration of approximately $1.2 billion were the three major deals that contributed 51.7 per cent of the total deal value during July 2022, added the report.
In addition, it said that the industry reported 92 Venture Capital (VC) deals worth $2.2 billion in July 2022, compared to the last 12-month average (July 2021 to June 2022) of 158 deals worth $4.2 billion.
Areteia Therapeutics raising $350 million in series A round of financing to establish Areteia and advance dexpramipexole through phase-III clinical trials, secure commercial supply, and pursue potential next-generation medicines; Cleerly raising $223 million in Series C round of financing; and Carmot Therapeutics raising $160 million in series D round of financing to advance clinical pipeline of novel incretin receptor modulators, were the major VC deals reported in July 2022.
Thank you very much for presenting this data about good website.